Meet the Leading Women in Biotech
To celebrate International Women's Day, The Tech Corner is featuring the most successful women in leadership roles in the European biotech industry. Despite the apparent resistance to women’s leadership and the industry’s accusations of gender inequalities, these women have made their mark and are paving the way to the future of the biotech industry.
Karen Aiach, Founder & CEO, Lysogene (Paris, France)
Karen Aiach, Founder and Managing Director, Lysogène. Under her leadership, Lysogene has raised €16.5M by developing new drug candidates to treat two rare, devastating and fatal central nervous system disorders in children for which, no treatment had previously existed: Sanfilippo syndrome type A (MPS IIIA) and GM1 gangliosidosis (or Landing disease). Karen Aiach founded Lysogene after her daughter was diagnosed with the first affliction. Lysogène has now finished its first clinical trial and has received a Rare Pediatric Disease Designation from the FDA for its pioneering research in gene therapy.
Lysogene is the first biotechnology company in 2017 to have joined the 52 biotechnology companies already listed on Euronext markets. On 8 February 2017, Lysogene’s successful IPO date, Lysogene was enabled to raise a total of €22.6 million, with its market capitalisation rising to €82.1 million. Watch her interview at the listing ceremony here .
Dominique Costantini, CEO, OSE Immunotherapeutics (Paris, France)
Dr. Dominique Costantini has over twenty years of experience in pharmaceutical research and innovation and has been central to the creation and merger of several biotech companies. Dr. Dominique Costantini was the co-founder and CEO of OSE Pharma in 2012, which made up half of the merger and creation of OSE Immunotherapeutics, and she remains the CEO and Director of the company today. OSE Immunotherapeutics is a biotechnology company dedicated to the development of innovative immunotherapies. The company specializes in the development of innovative treatments to activate or regulate the immune system and restore system disorders in the fields of immuno-oncology, autoimmune diseases and transplantation.
She also founded BioAlliance Pharma (renamed Onxeo in 2014) in 1997 and lead the company to its IPO on Euronext in 2005. Ms. Costantini held the position of Chief Executive Officer at Onxeo until 2011. Onxeo has a current market cap of 125M€ .
OSE Immunotherapeutics was first introduced onto the Euronext Paris market (Compartment C) in March 2015. Its market capitalization currently stands at €88m. OSE Immunitherapics was ranked 8th in the national Technology Fast 50 rankings and 3rd in its sector (‘Biotech and Life Sciences’) in 2016.
Maryvonne Hiance, Vice Chairman, OSE Immunotherapeutics (Nantes, France)
Maryvonne Hiance is the Vice Chairman of the board of OSE Immunotherapeutics, she co-founded and was Chairman of the Board of Effimune which merged with OSE pharma to form her current company in 2012. Effimune was a biotechnology company specialized in immune regulation with clinical applications in autoimmunity, transplantation and immune-oncology. She was awarded by France Biotech for her entrepreneurial achievements with Effimune in 2016 prior to the merger with OSE pharma, which was also adjacently rewarded for the same efforts.
OSE Immunotherapeutics currently holds a portfolio of advanced immunotherapy products in clinical phases 2 and 3, of promising products in preclinical phase and of potential drug candidates in R&D.
Euronext is the market of choice for life sciences companies, with 56 new life sciences listings since January 2011, raising a total of €1.5bn.Euronext launched a new quarterly Biotech Barometer, an infographic of key trends and figures about the Biotechs listed on Euronext’s markets provided by Euronext’s Post-Listing Services and BiotechBourse.
To read about more women who have been successful leaders and innovators in the Biotech industry check out Labiotech's article.
 On the day of its IPO, 8 February 2017
 As of 07/03/17
 Data as of end of February 2017